Clinical trials
1 active trial in South Africa
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)
Updated
Reviewed by Vidhi Upadhyay
South Africa Insulin Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Type, Delivery, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$74.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $25.1 Mn | — | — |
| 2025 (base) | $28.9 Mn | +$3.8 Mn | — |
| 2026 (forecast) | $33.3 Mn | +$4.4 Mn | +15.2% |
| 2027 (forecast) | $38.4 Mn | +$5.1 Mn | +32.7% |
| 2028 (forecast) | $44.2 Mn | +$5.8 Mn | +52.9% |
| 2029 (forecast) | $51.0 Mn | +$6.7 Mn | +76.1% |
| 2030 (forecast) | $58.7 Mn | +$7.7 Mn | +102.9% |
| 2031 (forecast) | $67.6 Mn | +$8.9 Mn | +133.7% |
| 2032 (forecast) | $77.9 Mn | +$10.3 Mn | +169.3% |
| 2033 (forecast) | $89.7 Mn | +$11.8 Mn | +210.2% |
| 2034 (forecast) | $103.4 Mn | +$13.6 Mn | +257.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $28.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $103.4 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 15.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, delivery and end user (see all) |
| Key players | Biocon, Viatris, Sanofi, Eli Lilly and Company, Gan & Lee Pharmaceuticals and 1 more (see all) |
| Regulator in South Africa | SAHPRASource: South African Health Products Regulatory Authority. Checked 14 Nov 2026. |
| Active clinical trials | 1 in South AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Insulin biosimilars are lower-cost versions of branded insulins that work the same way, improving access to diabetes treatment.
Key segments of the insulin Biosimilars market include type (Long-Acting, Rapid-Acting and Premixed) and delivery (Vials, Pens and Cartridges).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the insulin Biosimilars market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the insulin Biosimilars market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the insulin Biosimilars market. Long-term safety data and lifestyle support are still needed for many patients.
The insulin Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The South African Health Products Regulatory Authority (SAHPRA) registers medicines.[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.[2] ClinicalTrials.gov lists 1 study on Insulin Biosimilars that is recruiting, active or about to start in South Africa.[3] Diabetes (adults): 13.9% of adults in 2022, the latest WHO figure for South Africa.[4]
[1] South African Health Products Regulatory Authority. Checked 14 Nov 2026.
[2] National Department of Health. Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
[4] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for insulin Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in South Africa.
What doctors and scientists are doing in Insulin Biosimilars right now, from free public sources.
1 active trial in South Africa
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)13.9 % of adults
Diabetes (adults), South Africa, 2022 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 18 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
From our blog
South Africa
South Africa
South Africa
South Africa
South Africa
South Africa
Medical Devices · South Africa
Medical Devices · South Africa
Medical Devices · South Africa
Healthcare Services · South Africa
Healthcare Services · South Africa
Healthcare Services · South Africa